Black Diamond Therapeutics Appoints Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer
June 01, 2022 07:00 ET
|
Black Diamond Therapeutics, Inc
- Dr. Yurasov brings over 25 years of experience in oncology drug development and regulatory expertise - CAMBRIDGE, Mass. and NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics,...
Black Diamond Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 07:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine
May 12, 2022 16:30 ET
|
Black Diamond Therapeutics, Inc
- Peer-reviewed publication highlights 22 new oncogenic HER2 driver mutations identified and experimentally validated with MAP discovery engine - CAMBRIDGE, Mass. and NEW YORK, May 12, 2022 (GLOBE...
Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022 16:30 ET
|
Black Diamond Therapeutics, Inc
Dosed first patient in Phase 1 Study of BDTX-1535 for the treatment of glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC) including those with central nervous system (CNS) tumors;...
Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment
April 25, 2022 09:00 ET
|
Black Diamond Therapeutics, Inc
– Strategic areas of focus on development of BDTX-1535 and BDTX-4933 as well as MAP platform enabled small molecule drug discovery efforts – – Company to discontinue development of BDTX-189 and...
Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer
April 18, 2022 07:00 ET
|
Black Diamond Therapeutics, Inc
- Clinical update expected in second half of 2023 - CAMBRIDGE, Mass. and NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology...
Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference
April 07, 2022 16:30 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors
April 07, 2022 07:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 17, 2022 17:00 ET
|
Black Diamond Therapeutics, Inc
IND allowed by U.S. FDA and Phase 1 study of BDTX-1535 initiated for the treatment of GBM and NSCLC including those with CNS metastasesPreclinical data demonstrating the potential of MasterKey...
Black Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
March 02, 2022 08:00 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...